Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of S-217622 versus placebo in non-hospitalized adults with COVID-19
PACTR202303499747084Phase 3Recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing S-217622 with Placebo (2 arms). Primary endpoint: Composite outcome: hospitalization from any cause or death from any cause. Started Oct 2022; status: recruiting.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202303499747084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202303499747084.